Overview

A Study to Evaluate Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of Tripegfilgrastim in Pediatric Solid Tumor/Lymphoma Patients

Status:
Completed
Trial end date:
2018-11-01
Target enrollment:
Participant gender:
Summary
This is an open-label, single ascending dose study to evaluate safety, tolerability, and pharmacokinetics/pharmacodynamics of Tripegfilgrastim in pediatric solid tumor/lymphoma patients
Phase:
Phase 1
Details
Lead Sponsor:
Dong-A ST Co., Ltd.